Brolucizumab offers improved anatomical outcomes and extended dosing intervals compared to aflibercept, reducing treatment burden. However, postmarketing surveillance and real-world studies have highlighted safety concerns, including intraocular inflammation (IOI), retinal vasculitis, and retinal vascular occlusion, necessitating risk management strategies. To address these concerns, a comprehensive review of clinical trials, real-world data, and safety reports were conducted by an expert panel.
View Article and Find Full Text PDFGenes (Basel)
July 2025
: Senior-Loken syndrome (SLS) is a rare autosomal recessive renal-retinal disease caused by mutations in 10 genes. This study aimed to review the ophthalmic findings, renal function, and genotypes of Korean SLS cases. : We retrospectively reviewed 17 genetically confirmed SLS patients in Korea, including 9 newly identified cases and 8 previously reported.
View Article and Find Full Text PDF